INDP

Indaptus Therapeutics, Inc. is a pre-clinical stage biotechnology company developing novel therapeutics for cancer treatment. The company's approach focuses on targeting the tumor microenvironment and cancer metabolism to disrupt cancer cell survival mechanisms. Indaptus is advancing its lead programs through preclinical development with the goal of initiating clinical trials. The company's technology platform aims to identify and exploit cancer-specific vulnerabilities that can be addressed with small molecule or biologic therapies.